arrow
J

Jacob John

University of London
H指数:37
被引数:6,494

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Burden of antimicrobial resistance in culture-confirmed Salmonella Typhi isolates in India from 1977 to 2024: A systematic review and meta-analysis

1977年至2024年印度培养确诊沙门氏菌Typhi菌株中抗菌药物耐药负担:一项系统评价和荟萃分析

2026-04-010
PRE
Emergence of carbapenem-resistant Salmonella Typhi harboring blaNDM-5 in India: genomic evidence from a multicenter study

印度出现携带blaNDM-5的碳青霉烯耐药沙门氏菌Typhi:多中心研究的基因组学证据

2025-12-030
OAAI
Consultation report-considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries

咨询报告——关于在流行国家使用二价伤寒沙门氏菌/副伤寒甲型沙门氏菌疫苗的监管路径的考虑因素

VACCINE
IF3.5
2025-05-010
OAAI
Antimicrobial susceptibility trends of S. Typhi and S. Paratyphi in a post-COVID-19 pandemic India, from a multicenter surveillance network

后COVID-19疫情时代印度S. Typhi和S. Paratyphi的抗菌药物敏感性趋势,来自多中心监测网络

2025-04-210
OA
Recent emergence of cephalosporin-resistant Salmonella Typhi in India due to the endemic clone acquiring IncFIB(K) plasmid encoding blaCTX-M-15 gene
2025-04-010
OAAI
SARS-CoV-2 infections before, during, and after the Omicron wave: a 2-year Indian community cohort study

在Omicron波之前,期间和之后的SARS-CoV-2感染: 一项为期2年的印度社区队列研究

2024-09-012
PRE
Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study
2024-03-013
OAAI
Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELDTM) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study

ChAdOx1 nCoV-19 (COVISHIELDTM) 和BBV152 (COVAXIN) 的同源和异源加强疫苗接种的免疫原性和安全性®): 非劣效性第4阶段,参与者和观察者盲法,随机研究

2023-05-0115
OAAI
Genomic analysis unveils genome degradation events and gene flux in the emergence and persistence of S. Paratyphi A lineages
2023-04-282
OAAI
Burden of Typhoid and Paratyphoid Fever in India
2023-04-2023
OAAI